Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 737386, 6 pages
Research Article

Anticancer Effects of Geopropolis Produced by Stingless Bees on Canine Osteosarcoma Cells In Vitro

1Surgery and Orthopedics Department, Medical School, São Paulo State University (UNESP), 18618-970 Botucatu, SP, Brazil
2Investigative and Comparative Pathology Laboratory, College of Veterinary Medicine and Animal Husbandry, São Paulo State University (UNESP), 18618-970 Botucatu, SP, Brazil
3Department of Microbiology and Immunology, Biosciences Institute, São Paulo State University (UNESP), 18618-970 Botucatu, SP, Brazil

Received 2 January 2013; Revised 28 March 2013; Accepted 1 April 2013

Academic Editor: Ewelina Szliszka

Copyright © 2013 Naiara Costa Cinegaglia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Geopropolis is produced by indigenous stingless bees from the resinous material of plants, adding soil or clay. Its biological properties have not been investigated, such as propolis, and herein its cytotoxic action on canine osteosarcoma (OSA) cells was evaluated. OSA is a primary bone neoplasm diagnosed in dogs being an excellent model in vivo to study human OSA. spOS-2 primary cultures were isolated from the tumor of a dog with osteosarcoma and incubated with geopropolis, 70% ethanol (geopropolis solvent), and carboplatin after 6, 24, 48, and 72 hours. Cell viability was analyzed by the crystal violet method. Geopropolis was efficient against canine OSA cells in a dose- and time-dependent way, leading to a distinct morphology compared to control. Geopropolis cytotoxic action was exclusively due to its constituents since 70% ethanol (its solvent) had no effect on cell viability. Carboplatin had no effect on OSA cells. Geopropolis exerted a cytotoxic effect on canine osteosarcoma, and its introduction as a possible therapeutic agent in vivo could be investigated, providing a new contribution to OSA treatment.